Shareholders Equity: The sum of preferred and common equity items.
Sinovac Biotech, Ltd. (SVA) had Shareholders Equity of $10.29B for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$361.37M |
|
$90.91M |
|
$140.69M |
|
$220.69M |
|
$866.91M |
|
$-505.54M |
|
$548.37M |
|
$42.84M |
|
$42.84M |
|
$40.66M |
|
$40.66M |
|
$40.66M |
|
$40.66M |
|
$-505.54M |
|
$-394.26M |
|
71.86M |
|
71.86M |
|
$1.27 |
|
$1.27 |
|
| Balance Sheet Financials | |
$10.64B |
|
$880.97M |
|
$1.69B |
|
$12.34B |
|
$1.45B |
|
$163.84M |
|
$591.95M |
|
$2.04B |
|
$10.29B |
|
$10.14B |
|
|
Shareholders Equity |
$10.29B |
71.86M |
|
| Cash Flow Statement Financials | |
$-56.89M |
|
$456.36M |
|
$-823.95M |
|
$1.13B |
|
$602.22M |
|
$-526.90M |
|
-- |
|
$-947.00M |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.33 |
|
-- |
|
-- |
|
0.02 |
|
0.04 |
|
61.07% |
|
-139.89% |
|
-139.89% |
|
-109.10% |
|
11.85% |
|
25.16% |
|
$-152.69M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
1.45 |
|
1.12 |
|
325.24 |
|
0.40% |
|
0.40% |
|
0.33% |
|
0.39% |
|
$143.24 |
|
$-2.12 |
|
$-0.79 |
|